Latest MiMedx Group Inc. Stories
KENNESAW, Ga., May 1, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NasdaqCM: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2013. Highlights of First Quarter 2013 Results include: Revenue exceeded forecast for fifth consecutive quarter Revenue more than triples over first quarter of 2012 Fifth consecutive quarter...
MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on April 25, 2013 KENNESAW, Ga., April 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol "MDXG." Trading on NASDAQ is expected to...
KENNESAW, Ga., April 16, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2013, will be released before the opening of the market on Wednesday, May 1, 2013. MiMedx will host a live broadcast of its first quarter conference call on Wednesday, May 1, 2013 at...
KENNESAW, Ga., April 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 1(st) Annual Regen Med Investor Day in New York. Michael J. Senken, Chief Financial Officer and Donald B. Ayers, Vice President, National Strategic Accounts, are scheduled to present on April 17(th) at 5:00 p.m....
KENNESAW, Ga., March 18, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that MiMedx management has received a number of inquiries regarding trading activity in its shares late last week and the resultant drop in the trading price for the Company's common stock. After investigation, management believes that...
KENNESAW, Ga., March 14, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on...
KENNESAW, Ga., March 7, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2012. Highlights of 2012 Results include: Tripling of Revenue over 2011 First full year of positive Adjusted EBITDA Adjusted EBITDA increased by nearly $9 million Gross Margins at record...
KENNESAW, Ga., Feb. 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts," with a grant date of January 22, 2013. The U.S...
KENNESAW, Ga., Feb. 7, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter ended December 31, 2012, will be released before the opening of the market on Thursday, March 7, 2013. MiMedx will host a live broadcast of its fourth quarter conference call on Thursday, March 7, 2013...
KENNESAW, Georgia, Dec. 11, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that they will present at the 6(th) Annual OneMedForum in San Francisco. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on...
